JP2020522261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522261A5 JP2020522261A5 JP2019566609A JP2019566609A JP2020522261A5 JP 2020522261 A5 JP2020522261 A5 JP 2020522261A5 JP 2019566609 A JP2019566609 A JP 2019566609A JP 2019566609 A JP2019566609 A JP 2019566609A JP 2020522261 A5 JP2020522261 A5 JP 2020522261A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 20
- 101710043865 Nectin-4 Proteins 0.000 claims 17
- 102100035486 Nectin-4 Human genes 0.000 claims 17
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 101001023705 Homo sapiens Nectin-4 Proteins 0.000 claims 3
- 102000043460 human nectin4 Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000002055 immunohistochemical effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515454P | 2017-06-05 | 2017-06-05 | |
| US62/515,454 | 2017-06-05 | ||
| PCT/US2018/035840 WO2018226578A1 (en) | 2017-06-05 | 2018-06-04 | Nectin-4-binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522261A JP2020522261A (ja) | 2020-07-30 |
| JP2020522261A5 true JP2020522261A5 (cg-RX-API-DMAC7.html) | 2021-07-26 |
| JP7168590B2 JP7168590B2 (ja) | 2022-11-09 |
Family
ID=64566092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566609A Active JP7168590B2 (ja) | 2017-06-05 | 2018-06-04 | ネクチン４結合性タンパク質及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11292837B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3635013A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7168590B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102723905B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN111051345A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019025513A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3065514A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019014318A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI870338B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018226578A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| CN110904073B (zh) * | 2019-05-31 | 2020-12-01 | 江南大学 | 一种脂肪酶突变体及其在去污方面的应用 |
| WO2021069508A1 (en) * | 2019-10-07 | 2021-04-15 | Université D'aix-Marseille | Antibodies having specificity for nectin-4 and uses thereof |
| KR102280672B1 (ko) * | 2019-12-20 | 2021-07-23 | 주식회사 베르티스 | 암의 진단용 조성물 |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| US20230235054A1 (en) * | 2020-06-18 | 2023-07-27 | Bioatla, Inc. | Conditionally active anti-nectin-4 antibodies |
| EP4168039A4 (en) * | 2020-06-19 | 2024-12-04 | Agensys, Inc. | MARKER FOR USE IN METHODS OF TREATING CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC) |
| AU2021337687A1 (en) * | 2020-09-04 | 2023-03-23 | CSPC Megalith Biopharmaceutical Co., Ltd., | Nectin-4 antibodies and uses thereof |
| JP7458686B2 (ja) * | 2020-09-16 | 2024-04-01 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用 |
| US20240325557A1 (en) * | 2020-11-25 | 2024-10-03 | Innate Pharma | Treatment of cancer |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| CN116917324A (zh) * | 2021-04-26 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途 |
| US12258402B2 (en) | 2022-01-12 | 2025-03-25 | Navi Bio-Therapeutics, Inc. | Antibody specific to nectin cell adhesion molecule 4 and uses thereof |
| US20250205353A1 (en) | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| WO2023198008A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Compositions and methods for treating cancer |
| EP4310101A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibodies and antibody-drug conjugates |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| KR102584898B1 (ko) * | 2022-10-24 | 2023-10-04 | 연세대학교 산학협력단 | 자궁내막암 진단 방법 및 이를 이용한 키트 |
| CN119101156A (zh) * | 2023-06-08 | 2024-12-10 | 江苏迈威康新药研发有限公司 | 结合Nectin-4的抗体及其用途 |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111076A1 (en) * | 2004-05-12 | 2005-11-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4 (n4) as a marker for cancer prognosis |
| GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| JP2012511305A (ja) * | 2008-12-12 | 2012-05-24 | オンコセラピー・サイエンス株式会社 | 癌の治療および診断の標的遺伝子としてのネクチン−４ |
| TWI882308B (zh) | 2010-09-29 | 2025-05-01 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
| WO2016203053A2 (en) * | 2015-06-18 | 2016-12-22 | Thomas Mole Herd | Methods of characterising cancer |
| JP6985252B2 (ja) | 2015-09-09 | 2021-12-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ネクチン−４に対する特異性を有する抗体及びその使用 |
-
2018
- 2018-06-04 BR BR112019025513-3A patent/BR112019025513A2/pt unknown
- 2018-06-04 CN CN201880049820.6A patent/CN111051345A/zh active Pending
- 2018-06-04 WO PCT/US2018/035840 patent/WO2018226578A1/en not_active Ceased
- 2018-06-04 TW TW107119234A patent/TWI870338B/zh active
- 2018-06-04 CN CN202010492265.3A patent/CN111675761B/zh active Active
- 2018-06-04 CA CA3065514A patent/CA3065514A1/en active Pending
- 2018-06-04 KR KR1020197038453A patent/KR102723905B1/ko active Active
- 2018-06-04 EP EP18813335.9A patent/EP3635013A4/en active Pending
- 2018-06-04 JP JP2019566609A patent/JP7168590B2/ja active Active
- 2018-06-04 US US16/619,439 patent/US11292837B2/en active Active
- 2018-06-04 MX MX2019014318A patent/MX2019014318A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522261A5 (cg-RX-API-DMAC7.html) | ||
| ES2692522T3 (es) | Anticuerpo anti-cMet y su utilización para la detección y el diagnóstico del cáncer | |
| RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2021500916A5 (cg-RX-API-DMAC7.html) | ||
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2013506428A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535257A5 (cg-RX-API-DMAC7.html) | ||
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| AU2013302620B2 (en) | Stem cell enhancing therapeutics | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2014512809A5 (cg-RX-API-DMAC7.html) | ||
| JP2017149720A5 (cg-RX-API-DMAC7.html) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| WO2014089209A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| JP2017507131A5 (cg-RX-API-DMAC7.html) | ||
| JP2015503909A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516400A5 (cg-RX-API-DMAC7.html) | ||
| JP2014518630A5 (cg-RX-API-DMAC7.html) | ||
| JP2024029261A5 (cg-RX-API-DMAC7.html) | ||
| JP2018525320A5 (cg-RX-API-DMAC7.html) | ||
| EP3954999B1 (en) | Compositions and methods for detecting and treating ovarian cancer | |
| JP2018508467A (ja) | 抗ｉｌ−３４抗体 | |
| CA3058263C (en) | Compositions and methods for detecting prostate cancer | |
| JP2019048895A5 (cg-RX-API-DMAC7.html) |